The proposed acquisition marks Jagsonpal’s strategic entry into the hospital segment and is aligned with the Company’s long-term vision of strengthening its presence in India’s growing healthcare ecosystem.
Aequitas Healthcare, incorporated on September 7, 2017, is engaged in the sale and distribution of pharmaceutical products to hospitals. The company reported revenue from operations of ₹53.31 crore in FY26, ₹56.19 crore in FY25, and ₹53.71 crore in FY24.
ALSO READ | Share Buyback: A ₹1,100 crore drugmaker will be repurchasing its shares for the first time
The acquisition consideration is ₹20.8 crore for an 85% stake and will be funded through internal accruals. The transaction is expected to be completed by July 15, 2026 and does not require any governmental or regulatory approvals.
Post completion, Jagsonpal Pharmaceuticals will acquire control of Aequitas Healthcare, while the existing directors of Aequitas will retain a 15% stake and continue association with the business.
Manish Gupta, Managing Director, Jagsonpal, stated, “The proposed acquisition of Aequitas represents an important strategic milestone for Jagsonpal. It provides us with a ready platform for a meaningful presence in the hospital segment, which now contributes 10% of pharma industry sales and is growing faster.
ALSO READ | Buyback Alert: Shareholders of this ₹1,400 crore drugmaker approve repurchase plan; Check premium
We strongly believe that Jagsonpal’s portfolio of established brands will greatly benefit from Aequitas’ strong institutional relationships, delivering sustainable long-term value to our shareholders.”
The company said the acquisition provides access to hospital channels and institutional doctor networks, supporting faster relationship building compared to organic expansion. Aequitas Healthcare operates primarily in India and is headquartered in Mumbai.
Amrut Medhekar, Chief Operating Officer, Jagsonpal stated, “This transaction is a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to omnichannel specialty healthcare business in India and is reflective of our long-term commitment to building scalable, high-quality healthcare delivery in India. We look forward to unlocking value through operational excellence, disciplined execution, and patient-centric growth.”
Shares of Jagsonpal Pharmaceuticals Ltd ended at ₹230.80, down by ₹8.05, or 3.61%, on the BSE.
ALSO READ | Jagsonpal Pharma surges 12% after buyback plan of up to 16 lakh shares at ₹250 each
(Edited by : Jomy Jos Pullokaran)
